Currently admitted in Florida only. Practicing under the supervision of D.C. Bar members.
Kirsten Weigel-Van Aken, M.D. is an associate in Sterne Kessler’s Biotechnology & Chemical Practice Group. Kirsten assists in worldwide procurement of patents in biotechnology, chemical and pharmaceutical industries. Her expertise includes patent prosecution in the areas of gene therapy, biologics, therapeutic antibodies, cell therapies, vaccines, diagnostics, and small and large molecule formulations.
Prior to joining Sterne Kessler, Kirsten worked at an intellectual property law firm in Gainesville, FL where she assisted with patent prosecution.
Kirsten received her M.D. from the University of Heidelberg, Germany. Kirsten’s graduate research focused on the role of T cell subpopulations in the immune response to gynecological cancers. Kirsten performed a postdoctoral research fellowship at the University of Indianapolis, Department of Microbiology & Immunology, where she worked on developing AAV-based viral gene therapy vectors. Kirsten joined the faculty at the University of Florida Department of Pediatrics in the Division of Cellular & Molecular Therapy where she developed parvovirus based gene therapy vectors to target hematopoietic stem cells and various cancers.
Kirsten was awarded a Research Fellowship from the German National Research Foundation, a University of Florida Junior Investigator Award, and a Florida Department of Health New Investigator Research Grant.
Kirsten received her J.D. from the University of Florida Levin College of Law, cum laude, where she was a managing editor for the Florida Law Review.
- “Lactic acid induces aberrant amyloid precursor protein processing by promoting its interaction with endoplasmic reticulum chaperone proteins.” Xu Xiang, Kirsten A Weigel-Van Aken. PLoS ONE, 2010.
- “Pharmacological activation of guanine nucleotide exchange factors for the small GTPase Rap1 recruits high-affinity beta1 integrins as coreceptors for parvovirus B19: improved ex vivo gene transfer to human erythroid progenitor cells.” Kirsten A Weigel-Van Aken. Human Gene Therapy 2009.
- “Role of integrin cross-regulation in parvovirus B19 targeting.” Kirsten A Weigel-Kelley, Mervin Yoder, Linyuan Chen, Arun Srivastava. Human Gene Therapy 2006.
- “Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry.” Kirsten A Weigel-Kelley, Mervin Yoder, Arun Srivastava. Blood 2003.
- “Adeno-associated virus type 2-mediated gene transfer: role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo.” Qing K, Li W, Zhong L, Tan M, Hansen J, Weigel-Kelley KA, Chen L, Yoder MC, Srivastava A. Journal of Virology, 2003.
- “Recombinant human parvovirus B19 vectors.” Weigel-Kelley KA, Srivastava A. Pathologie Biologie. 2002.
- “Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression.” Qing K, Hansen J, Weigel-Kelley KA, Tan M, Zhou S, Srivastava A. Journal of Virology, 2001.
- “Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells.” Weigel-Kelley KA, Yoder MC, Srivastava A. Journal of Virology, 2001.